Results from ADAPT OCULUS are expected to support a sBLA submission to the FDA to secure a label expansion for oMG.

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — Hypersensitivity reactions to injection fillers are rare and unpredictable, but when they occur, ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

The FDA has approved Argenx SE's (NASDAQ:ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult ...

Huonslab said Wednesday that Hydizyme, its self-developed recombinant human hyaluronidase injection, is expected to be approved in the second half of this year. Huonslab, a ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...

Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...

October 9, 2012 (Berlin, Germany) — In a randomized, double-blind, comparator-controlled, 2-way crossover trial, 2 rapid-acting insulin analogs (lispro or aspart) formulated with recombinant human ...